Pharming appoints Robin Wright as chief financial officer

10 September 2015
pharming-big

Netherlands-based Pharming Group (Euronext: PHARM) has appointed Robin Wright as chief financial officer.

He will be responsible for the financial management, accounting and investor relations of Pharming. Mr Wright joins from the Swedish company Karolinska Development, where he was chief financial officer and head of business development. He also held the same role at Orexo, alaso based in Sweden.

Jaap Blaak, Pharming’s chairman of the board, commented: “We are very pleased that Robin can join Pharming at this exciting time as we complete our transformation from an R&D oriented biotech company to a self-sustainable specialty pharmaceutical company.  Robin’s experience, both as an operational CFO for public companies and as a former investment banker brings important additional strengths, experience and perspectives to the Board of Management and we look forward to confirming his appointment”.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical